Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
GTLS Chart Industries $78.31 0.38 (0.49%) 09:14 10/01/18 10/01 09:14 10/01/18 09:14 Conference/Events	Chart Industries to hold a conference call » Management holds a… Management holds a conference call to discuss the Company's agreement to sell it's oxygen-related products business to NGK Spark Plug Co., Ltd. will be held on October 1 at 9:30 am. Webcast Link 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GTLS Chart Industries $78.31 0.38 (0.49%) 08:10 10/01/18 10/01 08:10 10/01/18 08:10 Hot Stocks	Chart Industries to divest oxygen-related products business for $133.5M » Chart Industries… Chart Industries announced that it has signed a definitive agreement to divest its oxygen-related products business within the BioMedical segment to NGK Spark Plug for $133.5M. The sale is expected to close within the Q4, following the satisfaction of customary closing conditions, including regulatory requirements. The strategic decision to divest the oxygen-related products business reflects Chart's strategy and capital allocation approach to focus on its core capabilities and offerings. The sale of the oxygen-related products is a reallocation of capital from that business to a very strategic addition to Chart, VRV s.p.a., for which a definitive acquisition agreement was announced last week. In conjunction with this reallocation of capital to our core businesses, the realignment of segmentation geographically will support the significant growth opportunities and cost synergies that VRV brings to Chart as well as the anticipated 5% to 7% organic growth in 2019. A portion of the BioMedical segment related to Chart's cryogenic products and technological expertise is excluded from the sale. Chart's Cryobiological product line will be managed by and report through the distribution & storage Western Hemisphere segment, effective immediately. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
GTLS Chart Industries $76.03 -0.87 (-1.13%) 08:10 09/27/18 09/27 08:10 09/27/18 08:10 Hot Stocks	Chart Industries to acquire VRV for $147M » Chart Industries… Chart Industries announced the signing of a definitive agreement to acquire VRV s.p.a. and its subsidiaries. VRV is a diversified multinational corporation with highly automated, purpose-built facilities for the design and manufacture of pressure equipment serving the cryogenic and energy & petrochemical end markets. In connection with the acquisition, Chart has agreed to pay $147M, which will be funded by a combination of Chart's available cash on hand and debt under its current credit facility or another financing alternative, and assume the outstanding indebtedness of VRV. The acquisition is expected to add annual net sales of $115M in 2019, achieve significant cost synergies related to operational efficiencies and sourcing, and be EPS accretive in the first full year of ownership. The transaction is subject to customary closing conditions. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial

Over a month ago
AQST Aquestive Therapeutics $18.62 0.28 (1.53%) , BEAT BioTelemetry $58.80 -2.65 (-4.31%) … 08:28 09/13/18 09/13 08:28 09/13/18 08:28 Conference/Events	Lake Street to hold a conference » 2nd Annual Best Ideas… 2nd Annual Best Ideas Growth (BIG) Conference will be held in New York on September 13. AQST Aquestive Therapeutics $18.62 0.28 (1.53%) BEAT BioTelemetry $58.80 -2.65 (-4.31%) CRY CryoLife $34.25 -0.35 (-1.01%) DPLO Diplomat Pharmacy $19.13 -0.03 (-0.16%) ESIO Electro Scientific $17.85 -0.12 (-0.67%) FARM Farmer Bros. $27.90 -0.3 (-1.06%) GTLS Chart Industries $75.37 0.38 (0.51%) HIIQ Health Insurance Innovations $52.55 -2.5 (-4.54%) IDSY I.D. Systems $6.24 (0.00%) JYNT Joint Corp. $8.39 0.055 (0.66%) KIN Kindred Biosciences $13.80 -0.25 (-1.78%) LMAT LeMaitre $34.47 0.32 (0.94%) RST Rosetta Stone $15.04 -0.2 (-1.31%) STKS One Group Hospitality $3.29 0.12 (3.79%) TST TheStreet $2.12 0.03 (1.44%) USAT USA Technologies $10.15 0.95 (10.33%) WAAS AquaVenture $17.18 -0.15 (-0.87%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	13 Sep 13 Sep 13 Sep 13 Sep 24 Sep 27 Sep 27 Sep 13 Oct 21 Oct 15 Nov
GTLS Chart Industries $76.22 0.92 (1.22%) 04:55 08/30/18 08/30 04:55 08/30/18 04:55 Conference/Events	Chart Industries management to meet with Seaport Global » Meetings to be held in… Meetings to be held in the Midwest August 29-30 hosted by Seaport Global. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	30 Aug 13 Sep

GTLS Chart Industries $75.30 -0.29 (-0.38%) 04:55 08/29/18 08/29 04:55 08/29/18 04:55 Conference/Events	Chart Industries management to meet with Seaport Global » Meetings to be held in… Meetings to be held in the Midwest August 29-30 hosted by Seaport Global. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	29 Aug 30 Aug 13 Sep
GTLS Chart Industries $77.65 0.59 (0.77%) 06:15 08/22/18 08/22 06:15 08/22/18 06:15 Conference/Events	Chart Industries management to meet with Seaport Global » Meetings to be held in… Meetings to be held in the Midwest August 29-30 hosted by Seaport Global. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	29 Aug 30 Aug 13 Sep
GTLS Chart Industries $76.20 8.23 (12.11%) 14:10 07/19/18 07/19 14:10 07/19/18 14:10 Recommendations	Chart Industries analyst commentary at Craig-Hallum » Chart Industries Q2… Chart Industries Q2 impressive, but growth just starting, says Craig-Hallum. Craig-Hallum analyst Eric Stine raised his price target for Chart Industries to $91 from $89 and reiterates a Buy rating on the shares following the company's "impressive" Q2 results. The better than expected quarter again demonstrated "loud and clear" the "positive and accelerating trends" across the company's three business segments, Stine tells investors in a research note. The analyst points out that Chart's orders grew sequentially for the sixth consecutive quarter. He believes "this is just the start" for the company as many of its end markets are still at early stages of growth. Chart remains at the "very front end" of the current LNG market upcycle and the next LNG project wave, Stine writes. 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Jul 29 Aug 30 Aug
GTLS Chart Industries $67.97 0.88 (1.31%) 06:11 07/19/18 07/19 06:11 07/19/18 06:11 Hot Stocks	Chart Industries CEO sees higher sales, earnings in 2H18 » "Our second quarter… "Our second quarter results reflect the past three quarters' order strength. With the strength in packaged gas, order activity in Asia, and European LNG vehicle tank and trailer demand, combined with our right-sized cost structure, we expect to see the second half of 2018 at higher sales and earnings levels than the first half of the year," said Jill Evanko, Chart's President and CEO. "The $28 million Hudson order received in the second quarter for a large LNG project is exciting for our Energy & Chemicals segment, as it further demonstrates the strategic value of the combination of Hudson and Chart." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Jul 29 Aug 30 Aug
GTLS Chart Industries $67.97 0.88 (1.31%) 06:06 07/19/18 07/19 06:06 07/19/18 06:06 Hot Stocks	Chart Industries conducting review of oxygen-related product lines » Management said, "As… Management said, "As we announced at the end of the first quarter of 2018, we are conducting a strategic review of the oxygen-related product lines within our BioMedical segment, including an evaluation of a possible divestiture of the businesses. We are excluding from the review those portions of the BioMedical segment that utilize and align with our cryogenic technological expertise (Cryobiological). The asset group does not meet the criteria to be held for sale, and therefore continues to be accounted and reported for as assets to be held and used. There can be no assurance that this evaluation will result in any transaction being announced or consummated. The Company will not disclose further developments during this process until our Board of Directors has approved a specific action or we have determined that further disclosure is appropriate." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	19 Jul 29 Aug 30 Aug

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial